TRINETRA › Sectors › Healthcare
Rubicon Research Limited (RUBICON) — share price, P/E and fundamentals
Rubicon Research Limited (NSE: RUBICON) closed at ₹1,610.50 on 30 Oct 2026, +160.3% over one year, against a 52-week range of ₹570.75 – ₹1,899.00.
In the quarter ended 30 Jun 2026 (consolidated, filed 14 Aug 2026) it reported revenue of ₹534 cr and net profit of ₹85 cr, a 15.9% net margin.
On four consecutive filed quarters its trailing P/E is 92.4.
From the balance sheet dated 31 Mar 2026: return on equity 26.3%, ROCE 32.1%, debt-to-equity 0.20.
Against 65 Healthcare peers on NSE: Net margin higher than 59% of 63 sector peers; PBT margin higher than 60% of 63 sector peers; ROE higher than 89% of 63 sector peers.
Key figures
| Last close | ₹1,610.50 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -3.9% / +71.6% / +160.3% |
| 52-week low – high | ₹570.75 – ₹1,899.00 |
| Market capitalisation | ₹26,634 cr |
| Trailing P/E | 92.4 |
| Price / book | 20.67 |
| EV / EBITDA | 57.7 |
| Earnings yield | 1.1% |
| TTM EPS | ₹17.43 |
| TTM net profit | ₹288 cr |
| Quarter revenue | ₹534 cr |
| Quarter net profit | ₹85 cr |
| Net margin | 15.9% |
| Return on equity | 26.3% |
| ROCE | 32.1% |
| Debt / equity | 0.20 |
| Current ratio | 2.01 |
| Free cash flow | ₹-24 cr |
| Average daily turnover (50 days) | ₹36.7 cr |
Against Healthcare peers
| Metric | RUBICON | Peer median | Percentile |
|---|---|---|---|
| Net margin | 15.87 | 12.67 | 59 |
| PBT margin | 20.66 | 17.57 | 60 |
| ROE | 26.31 | 13.86 | 89 |
| ROCE | 32.11 | 16.59 | 87 |
| Debt / equity | 0.20 | 0.11 | 62 |
| Cash conversion | 0.83 | 1.25 | 21 |
| Trailing P/E | 92.41 | 43.07 | 92 |
| P/B | 20.67 | 5.88 | 100 |
Questions
What is the P/E ratio of Rubicon Research Limited?
Rubicon Research Limited's trailing P/E is 92.4, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026.
What were Rubicon Research Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Rubicon Research Limited reported revenue of ₹534 cr and net profit of ₹85 cr (consolidated), filed with the exchange on 14 Aug 2026.
What is Rubicon Research Limited's ROE?
Return on equity is 26.3% based on the balance sheet dated 31 Mar 2026.
Does Rubicon Research Limited have debt?
Debt-to-equity is 0.20 on the balance sheet dated 31 Mar 2026.
What is RUBICON's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, RUBICON traded between ₹570.75 and ₹1,899.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.